The first Kunitz domain of TFPI1 has already been utilized in a phage display–based drug development project that yielded the potent plasma kallikrein inhibitor, ecallantide (Kalbitor®), which is an FDA-approved drug for the treatment of acute attacks of hereditary angioedema (57, 58). Here, TFPI is linked to hereditary angioedema.